Because they are perceived as distinct from the biological sciences, entrepreneurial pursuits may be daunting to the average researcher. In this report, we explain why academic scientists and in particular translational researchers should be naturally as well as rationally attracted to entrepreneurial endeavors. We go into some detail of how entrepreneurial achievements are actually accomplished and offer a few caveats for consideration when embarking down entrepreneurial pathways. We conclude that, although not for everyone, for translational investigators in the biologic sciences, entrepreneurial pursuits are desirable, accomplishable, and professionally rewarding. (J Am Coll Cardiol Basic Trans Science 2018;3:1-8)
why faculty-based translational scientists may want to participate as entrepreneurs in the biotechnology innovation arena, and how this is typically done. We also describe some of the caveats or "howevers" that should be considered before embarking on such a journey.
Although academically generated IP can be licensed to a third party for development, the emphasis in this paper is on the application of IP to found start-up companies where the IP inventor or inventors are playing important entrepreneurial roles. In addition, we are using a more expansive definition of biotechnology beyond the original description of "the use of living organisms to make products or run processes" (8) to include any IP discovered by a translational researcher working in the biological sciences that is entered into commercial development by a life sciences company, defined by a focus on development of biotech, pharmaceuticals, or medical devices.
Creating a life sciences start-up provides the means of realizing the full potential of a discovery or a new technology, which generally cannot be achieved in an academic lab where direction is typically driven by trainees seeking to make open-ended new discoveries. In this regard, it is worth highlighting the distinctions between the goals of academia and biotech.
In academia, almost anything new can be interesting even when seemingly unrelated to a human disease or treatment, and the eventual connections between basic science discovery and a possible therapeutic might take decades to realize. In contrast, the primary goals of start-up companies are to optimize discoveries in a very directed way, which often translates into studies of toxicity, delivery, and pharmacodynamics. Such efforts are extremely important for therapeutic development and are not easily achieved in an academic laboratory.
WHY SHOULD TRANSLATIONAL SCIENTISTS CONSIDER ENGAGING IN ENTREPRENEURIAL ACTIVITIES?
POTENTIAL POSITIVE OUTCOMES. The reasons why academic scientists should consider becoming involved in entrepreneurial activities range from pursuit of positive outcomes to avoidance of some of the negative circumstances likely to be encountered in a typical career trajectory. If a scientist is able to use IP to found a company and then attract start-up investment, this will ordinarily be accompanied by research support to consolidate and extend the IP, some of which typically is done in the founding scientist's laboratory.
Depending on the strength of the IP, the licensing details of the IP, and the start-up characteristics, some of the funding may return to the scientist's laboratory for general research support, in exchange for a first option of review or license of any new IP related to the research support. In an age of near single-digit National Institutes of Health pay lines, any type of additional research funding is generally viewed favorably. Another, less obvious potential benefit of successful entrepreneurial activity is that its recognition may influence other investigators or companies to invest in the research area, increasing the chance that something from the research sector will ultimately be available to society.
Regardless of the details of any entrepreneurial activity, once launched, the academic scientist will be exposed to new scientific and nonscientific perspectives and activities, none of which would likely have been encountered outside of the new venture. For example, in the science arena, it is likely that techniques beyond the scientist's range of expertise will need to be employed, and to stay engaged in the IP development the founding scientist will need to become facile with them. Some of these might include high throughput screening and compound optimization, regulatory science, and clinical trial methodology. From the business side, the function of corporate governance, federal regulation, initial public offerings, and exit strategies will all become familiar to a scientist-founder. Bristow et al.
Entrepreneurialism in the Translational Biologic Sciences Work in human systems may be particularly valuable because it may allow for earlier patentability of IP, based on the direct connection to therapeutic outcomes.
AVOIDANCE OF NEGATIVE CAREER OBSTACLES.
On the negativity avoidance side of the ledger in Table 1 are situations that may or may not concern an academic scientist. For some of us the "unicorn"
career path portrayed in Figure 1 Traditional and nontraditional/entrepreneurial career paths available to academic scien- 
DETERMINANTS OF SUCCESS FOR BIOTECHNOLOGY
START-UPS. Some major determinants of success for biotechnology start-ups are given in Table 3 , in our estimated rank order.
I n t e l l e c t u a l p r o p e r t y . Assuming the founding scientists have no disqualifying characteristics, the most important determinant of start-up formation is IP. To 
be of high value, the IP that serves as a platform for the start-up ("actionable IP") should be patentable, address an unmet medical need, have the potential for a large return-on-investment, and be amenable to a cost-effective and executable development strategy (14) . Not only does IP need to meet these criteria, but the data and materials have to be developed to communicate these characteristics to potential investors. Table 4) . Although not all of the characteristics listed in Table 4 are or need to be inherent in successful scientist-entrepreneurs, typically most of these attributes are present and major deficiencies in any of them are potentially disqualifying to astute investors. Note that the career trajectory position is not listed as a factor; provided that criterion 1 in Table 4 is satisfied, a founder may be an early-, mid-, or late-career investigator. Also, in device start-ups, criterion 1 is not applicable. For device development there is less of a funding requirement and a shorter development time, and it is not uncommon for cardiovascular junior scientists to found companies. C o m p a n y d i r e c t i o n . Once a start-up company is founded and has secured its series A funding, there are a few "good business practices" that deserve mention. The first is that capital is precious, and operations need to proceed on the most parsimonious course that allows for meeting program objectives in a timely manner. The second is that to be successful in the context of finite resources, mistakes in direction or execution must be avoided, which means experienced personnel must be brought into management positions ranging from directors to company officers.
The choice of board members is another critical step.
Here the blending of multiple backgrounds relevant to the company's mission is the major challenge, followed closely by the choice of individuals with track records of working effectively with others.
The board and senior management are responsible for setting strategy, but equally important are the execution tactics that are the major responsibility of mid-level and project managers.
G e o g r a p h i c l o c a t i o n . We believe it is important to
consider where to locate a life sciences start-up.
Among the important factors are: 1) proximity to a major research university, typically that of a founder;
2) a region with enough ongoing sector business activity to have created a pool of qualified potential employees; 3) a locally favorable cost of living/quality of life index; and 4) a favorable business climate.
Collectively we have founded or co-founded companies in Northern California; Boulder/Denver, Colorado; Boston, Massachusetts; and Dallas, Texas, all of which at the time of founding satisfied the abovementioned criteria and were able to attract adequate human and financial capital. E x t e r n a l f a c t o r s . Table 3 Ideally should be at/close to the top or clearly headed for the top of their scientific field
Reputation for effective collaboration; should not be considered a difficult co-worker Stellar ethical reputation; should not be controversial
Willing to commit long-term to the mission of the start-up
Open to sharing the responsibilities and recognition with co-founders and senior management; "team player"
creative financing instruments such as reverse mergers had to be resorted to in order to maintain start-up viability. Luck and serendipity are always factors, at all levels of scientific activity. Serendipity plays a major role in scientific discovery as well as product development (17), and luck tends to favor a well-organized/opportunistic organization (18) as well as one that is unafraid of risk (19) .
HOWEVER, ENTREPRENEURIALISM IN THE TRANSLATIONAL SCIENCES IS NOT FOR EVERYONE
FAILURE IS THE MOST LIKELY OUTCOME. The sobering reality of academic scientist entrepreneurial endeavors is that the vast majority of them fail, at Bristow et al.
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